Hydroxyethyl starch: Here today, gone tomorrow

British Journal of Anaesthesia

Volumn 111, Issue 3, 2013, Pages 321-324

  Nolan, J P ^a   Mythen, M G ^b  

^a ROYAL UNITED HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN; HARTMANN SOLUTION; HETASTARCH; RINGER LACTATE SOLUTION; SODIUM CHLORIDE;

ACUTE KIDNEY FAILURE; CRITICALLY ILL PATIENT; CRYSTALLOID; DISEASE SEVERITY; FLUID RESUSCITATION; GLYCOCALYX; HEALTH CARE COST; INTENSIVE CARE; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY GRAFT; LENGTH OF STAY; META ANALYSIS (TOPIC); MICROCIRCULATION; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; SEPSIS; SURGICAL INFECTION; SYSTEMATIC REVIEW (TOPIC);

EID: 84882788735     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aet294     Document Type: Editorial

References (42)

1. Pharmacovigilance Risk Assessment Committee of the European Medicines Agency. Available fromhttp://www.ema.europa.eu/docs/ en-GB/document-library/ Press-release/2013/06/WC500144446.pdf (accessed 4 July 2013
2. MedicinesandHealthcareProductsRegulatoryAgency. Class2drug alert (action within 48 hours): Hydroxyethyl starch (HES) products-B Braun Melsungen AG and Fresenius Kabi Limited (EL (13)A/18). Available fromhttp://www.mhra.gov.uk/ Publications/Safetywarnings/ DrugAlerts/CON287025 (accessed 4 July 2013
3. Food and Drug Administration. FDA safety communication: Boxed warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings. 2013
4. Brickman RD, Murray GF, ThompsonWL, BallingerWFII. The antigenicity of hydroxyethyl starch in humans. Studies in seven normal volunteers. J Am Med Assoc 1966; 198: 1277-9
5. Finfer S, Liu B, Taylor C, et al. Resuscitation fluid use in critically ill adults: An international cross-sectional study in 391 intensive care units. Crit Care 2010; 14: R185
6. Grocott MP, Dushianthan A, Hamilton MA, Mythen MG, Harrison D, Rowan K. Perioperative increase in global blood flow to explicit defined goals and outcomes following surgery. Cochrane Database Syst Rev 2012; 11: CD004082
7. McIlroy DR, Kharasch ED. Acute intravascular volume expansion with rapidly administered crystalloid or colloid in the setting of moderate hypovolemia. Anesth Analg 2003; 96: 1572-7
8. Feldheiser A, Pavlova V, Bonomo T, et al. Balanced crystalloid compared with balanced colloid solution using a goal-directed haemodynamic algorithm. Br J Anaesth 2013; 110: 231-40
9. Dubin A, Pozo MO, Casabella CA, et al. Comparison of 6% hydroxyethyl starch 130/0.4 and saline solution for resuscitation of the microcirculation during the early goal-directed therapy of septic patients. J Crit Care 2010; 25: 659 e1-8
10. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-39
11. Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/ 0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367: 124-34
12. MyburghJA,Finfer S,BellomoR,etal.Hydroxyethyl starchorsalinefor fluidresuscitationinintensivecare.NEnglJMed2012;367: 1901-11
13. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013; 2: CD000567
14. Gattas DJ,DanA,MyburghJ, Billot L, LoS, Finfer S. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: Systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 2013; 39: 558-68
15. Patel A, Waheed U, Brett SJ. Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: Systematic review and meta-Analysis. Intensive Care Med 2013; 39: 811-22
16. Zarychanski R, Abou-Setta AM, Turgeon AF, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: A systematic reviewand meta-Analysis. J AmMed Assoc 2013; 309: 678-88
17. Haase N, Perner A, Hennings LI, et al. Hydroxyethyl starch 130/ 0.38-0.45 versus crystalloid or albumin in patients with sepsis: Systematic review with meta-Analysis and trial sequential analysis. Br Med J 2013; 346: F839
18. Gillies MA, Habicher M, Jhanji S, et al. Incidence of post-operative death and acute kidney injury associated with intravenous 6% hydroxyethyl starch use: Systematic review and meta-Analysis. Br J Anaesth 2013 (in press; doi:10.1093/bja/aet303
19. Legendre C, Thervet E, Page B, Percheron A, Noel LH, Kreis H. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993; 342: 248-9
20. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-Transplant recipients. Lancet 1996; 348: 1620-2
21. Neuhaus W, Schick MA, Bruno RR, et al. The effects of colloid solutions on renal proximal tubular cells in vitro. Anesth Analg 2012; 114: 371-4
22. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: A multicentre randomised study. Lancet 2001; 357: 911-6
23. Boldt J. Hydroxyethylstarch as a risk factor for acute renal failure in severe sepsis. Lancet 2001; 358: 581-3
24. Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: Different products-different effects. Anesthesiology 2009; 111: 187-202
25. Hartog CS, Skupin H, Natanson C, Sun J, Reinhart K. Systematic analysis of hydroxyethyl starch (HES) reviews: Proliferation of lowquality reviews overwhelms the results of well-performed meta-Analyses. Intensive Care Med 2012; 38: 1258-71
26. Lobo DN, Stanga Z, Aloysius MM, et al. Effect of volume loading with 1 liter intravenous infusions of 0.9% saline, 4% succinylated gelatine (Gelofusine) and 6% hydroxyethyl starch (Voluven) on blood volume and endocrine responses: A randomized, three-way crossover study in healthy volunteers. Crit Care Med 2010; 38: 464-70
27. Doherty M, Buggy DJ. Intraoperative fluids: How much is too much? Br J Anaesth 2012; 109: 69-79
28. Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: An improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth 2012; 108: 384-94
29. Bayer O, Reinhart K, Kohl M, et al. Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance,andpatientoutcomesin patients with severesepsis:aprospective sequential analysis. Crit Care Med 2012; 40: 2543-51
30. Harper NJ, Dixon T, DugueP, et al. Suspected anaphylactic reactions associated with anaesthesia. Anaesthesia 2009; 64: 199-211
31. Thomas-Rueddel DO, Vlasakov V, Reinhart K, et al. Safety of gelatin for volume resuscitation-A systematic review and meta-Analysis. Intensive Care Med 2012; 38: 1134-42
32. Hahn RG. Volume kinetics for infusion fluids. Anesthesiology 2010; 113: 470-81
33. Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 2011; 37: 86-96
34. Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: A systematic review and meta-Analysis. Crit Care Med 2011; 39: 386-91
35. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637
36. Guidet B, Mosqueda GJ, Priol G, Aegerter P. The COASST study: Costeffectiveness of albumin in severe sepsis and septic shock. J Crit Care 2007; 22: 197-203
37. Myburgh J, Cooper DJ, Finfer S, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007; 357: 874-84
38. Corcoran T, Rhodes JE, Clarke S, Myles PS, Ho KM. Perioperative fluid management strategies in major surgery: A stratified metaanalysis. Anesth Analg 2012; 114: 640-51
39. National Institute for Health and Care Excellence (NICE). Intravenous fluid therapy in adults in hospital. Available from http://www. nice.org.uk/nicemedia/live/13298/63879/63879.pdf (accessed 4 July 2013
40. Chowdhury AH, Cox EF, Francis ST, Lobo DN. A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lytew 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg 2012; 256: 18-24
41. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, BaileyM. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. J Am Med Assoc 2012; 308: 1566-72
42. McCluskey SA, Karkouti K, Wijeysundera D, Minkovich L, Tait G, Beattie WS. Hyperchloremia after noncardiac surgery is independently associated with increased morbidity and mortality: A propensity-matched cohort study. Anesth Analg 2013; 117: 412-21